Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 7, 2012, Pages 1722-1729

  Nalda Molina, R ^a,b   Dokoumetzidis, A ^a   Charkoftaki, G ^a   Dimaraki, E ^a   Margetis, K ^c   Archontaki, H ^a   Markantonis, S ^a   Boutos, N ^c   Sakas, D ^c   Vryonis, E ^d   Skoutelis, A ^d   Valsami, G ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Blood brain barrier; Central nervous system; Cerebrospinal fluid; Non linear mixed effects modelling

Indexed keywords

BACLOFEN; DORIPENEM;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COMPUTER PROGRAM; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PENETRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMPLANTATION; LUMBAR PUNCTURE; MINIMUM INHIBITORY CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; PREDICTOR VARIABLE; SINGLE DRUG DOSE; STEADY STATE;

ADULT; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CEREBROSPINAL FLUID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MODELS, STATISTICAL; PLASMA;

EID: 84862660906     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks106     Document Type: Article

References (40)

1. Raza M, Shad A, Peddler S et al. Penetration and activity of antibiotics in brain abscess. J Coll Physicians Surg Pak 2005; 15: 165-7.
2. Lutsar I, Friedland IR. Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid. Clin Pharmacokinet 2000; 39: 335-43.
3. Ostergaard C, Sandvang D, Frimodt-Moller N et al. High cerebrospinal fluid (CSF) penetration and potent bactericidal activity in CSF of NZ2114, a novel plectasin variant, during experimental pneumococcal meningitis. Antimicrob Agents Chemother 2009; 53: 1581-5.
4. Tunkel R, Hartman B, Kaplan S et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39: 1267-84.
5. Lebel H, McCracken G. Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children. Pediatrics 1989; 83: 161-7.
6. FDA 2007. FDA Approves New Drug to Treat Complicated Urinary Tract and Intra-Abdominal Infections. 17 October 2007. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109010.htm (4 January 2012, date last accessed).
7. Matthews SJ, Lancaster JW. Doripenem monohydrate, a broadspectrum carbapenem antibiotic. Clin Ther 2009; 31: 42-63.
8. Fritsche T, Stilwell M, Jones R. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect 2005; 11: 974-84.
9. Jones R, Huynh H, Biedenbach D et al. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 2004; 54: 144-54.
10. Kim A, Banevicius MA, Nicolau D. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob Agents Chemother 2008; 52: 2497-502.
11. Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various b-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005; 52: 71-4.
12. Castanheira M, Jones R, Livermore D. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn Microbiol Infect Dis 2009; 63: 426-33.
13. Horiuchi M, Kimura M, Tokumura M et al. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with b-lactam antibiotics. Toxicology 2006; 222: 114-24.
14. Kobayashi Y. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. J Infect Chemother 2005; 11: 259-61.
15. Mushtaq S, Ge Y, Livermore D. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized b-lactamases. Antimicrob Agents Chemother 2004; 48: 1313-9.
16. Sacar S, Turgut H, Toprak S et al. A retrospective study of central nervous system shunt infections diagnosed in a university hospital during a 4-year period. BMC Infect Dis 2006; 6: 43.
17. Margetis K, Dimaraki H, Charkoftaki G et al. Penetration of intact blood-brain barrier by doripenem. Antimicrob Agents Chemother 2011; 55: 3637-8.
18. Beal S, Sheiner L, Boeckman A (eds). NONMEM Users Guides. Ellicott City, MD: ICON Development Solutions, 1989-2006.
19. Ikeda K, Ikawa K, Morikawa N et al. Quantification of doripenem in human plasma and peritoneal fluid by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 867: 20-5.
20. Nandy P, Samtani M, Lin R. Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients. Antimicrob Agents Chemother 2010; 54: 2354-9.
21. Anderson B, Holford N, Woollard G et al. Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children. Br J Clin Pharmacol 1998; 46: 237-43.
22. Efron B, Tibshirani R. An Introduction to the Bootstrap. London/Boca Raton: Chapman & Hall/CRC Press, 1993.
23. Holford N. Wings for NONMEM Version 6.16. Auckland, New Zealand, February 2010. http://wfn.sourceforge.net (20 March 2012, date last accessed).
24. Yano Y, Beal S, Sheiner L. Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001; 28: 171-92.
25. Albane'se J, Léone M, Bruguerolle B et al. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother 2000; 44: 1356-8.
26. Alffenaar J, van Altena R, Bökkerink H et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis 2009; 49: 1080-2.
27. Lutsar I, McCracken G, Friedland I. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 1998; 27: 1117-27.
28. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther 2007; 82: 17-20.
29. Cirillo I, Vaccano N, Turner K et al. Pharmacokinetics, safety and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. J Clin Pharmacol 2009; 49: 798-806.
30. Norrby R. A review of the penetration of antibiotics into CSF and its clinical significance. Scand J Infect Dis 1978; 14: 296-309.
31. Lorenzo A, Spector R. The distribution of drugs in the central nervous system. Adv Exp Med Biol 1976; 69: 447-61.
32. Darville T. Imipenem and meropenem. Semin Pediatr Infect Dis 1999; 110: 38-44.
33. Colardyn F, Faulkner K. Intravenous meropenem versus imipenem/ cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group. J Antimicrob Chemother 1996; 38: 523-37.
34. Schmutzhard E, Williams K, Vukmirovits G et al. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group. J Antimicrob Chemother 1995; 36 Suppl A: 85-97.
35. Klugman KP, Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. Antimicrob Agents Chemother 1995; 39: 1140-6.
36. MERREM I.V. (meropenem for injection) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals, 2007.
37. Mohr JF III. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. Clin Infect Dis 2008; 47 Suppl 1: 41-51.
38. FDA. Merrem I.V. (meropenem for injection) for Intravenous Use Only. Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) - March 2008. http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm116270.htm (4 January 2012, date last accessed).
39. Gelfand M, Cleveland K, Mazumder S. Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 2009; 64: 1297-9.
40. Stucki A, Cottagnoud M, Acosta F et al. Efficacy of doripenem against Escherichia coli and Klebsiella pneumoniae in experimental meningitis. J Antimicrob Chemother 2012; 67: 661-5.